Novartis raised its full-year core operating income guidance to low single-digit growth after strong third-quarter demand for key cancer and multiple sclerosis drugs.
Novartis shares dropped 11% following a late-stage trial failure for drug del-desiran, sparking investor concerns over its M&A strategy and $12 billion Avidity acquisition amid patent expiry challenge
Artisan Partners urges Novartis board changes after failed drug trials wiped nearly $30 billion from its market value. The shareholder criticizes the company's M&A strategy and compensation structure,
ChemBrief